Animal Health USA 2020 | Kisaco Research

Animal Health Investment USA

Serving Unmet Medical Needs in Veterinary Medicine Through Business Partnering and Investment

Download Agenda
Virtual Event
12-14 October, 2020

“I had strong expectations for the conference, and they were far exceeded. The quality of the connections I made and the information learned will strengthen our company and help us succeed.”

Peter Alberti, CEO, Pet Cause Media

Why Attend

Animal Health Investment USA is the premier investment forum showcasing the most exciting partner opportunities in animal health and connecting those businesses together with financial investors and strategic corporate partners.


This year, in light of Covid-19, our event is now a virtual one. We appreciate that this will be a new experience for many of you but operating virtually is now the new business norm, at least for now, and we look forward to working with you to make this a truly effective experience.


For the discussions this year, we will be looking specifically at maximizing the therapeutic and commercial potential of human technologies and serving unmet medical needs in veterinary health. Additionally, we continue to be focused on driving investor engagement and showcasing the industry’s most exciting emerging companies.


We have keynote presentations and C-level panel discussions that address the trends and market dynamics of the animal health industry, across all species. A key element of the investment forum is our virtual, private meeting scheduler, available to all participants.

300+
Attendees
40+
Investors
80+
Start-ups
25+
Private Meetings per person

Animal Health has distinct advantages over human healthcare:

  1. The research and development process for animal health products is typically shorter and less expensive than for human therapeutics, as animal trials typically can be performed in the target species at an earlier stage, and shorter lifespans result in faster safety assessment and trial completion.
  2. A substantial portion of animal health R&D is focused on product life-cycle management as opposed to novel drugs, which also leads to less risky pipelines.
  3. Animal health medicines and vaccines face lower pressure from generic competition when compared to human healthcare peers.
  4. Animal health is primarily a cash business and does not face the same insurance/third party payer and drug pricing risks that can be an overhang on human therapeutics.

Speakers

 

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).

TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).

TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.

Michael also serves as Managing Partner of Covenant Animal Health Partners, a TechAccel subsidiary that focuses on development of “revenue-ready” animal health products for both companion and farm animals.

Before founding TechAccel, Michael served as the fifth President and Chief Executive Officer of MRIGlobal – one of the nation's most prominent research institutions. In his 14 years with MRIGlobal (formerly Midwest Research Institute), he led its growth from 2 to 17 national and international locations.

Michael has more than 30 years of experience working with the private sector and government agencies, including laboratory management positions at Applied Marine Research Laboratory in Norfolk, Va., and program management for the Harbor Branch Oceanographic Institution in Fort Pierce, Fla. He was President and Chairman of startup Brevard Teaching and Research Laboratories, a post he held until the company was acquired by MRIGlobal.

Michael received a Ph.D. in Chemical Toxicology/Oceanography from Old Dominion University and a B.S. in Biology from Allegheny College. He has been a panelist, keynote speaker, lecturer, reviewer to several journals, and is the author of numerous publications, articles, book chapters, and technical reports.

He has served on several boards, including Labconco Corp. Board of Directors and University of Missouri-Kansas City Board of Trustees, as well as numerous civic organizations. He is a contributing opinion writer for Forbes.com.

Michael lives in suburban Kansas City.

Email: [email protected]
LinkedIn www.linkedin.com/in/michaelhelmstetter/

 

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC
 

Kristin Bloink

Vice President, Global Research & External Innovation
Elanco Animal Health

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Vice President, Global Research & External Innovation
Elanco Animal Health

Kristin Bloink

Vice President, Global Research & External Innovation
Elanco Animal Health

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

Independent Animal Health Expert

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

 

Phil Austin

Founding Partner
Anterra Capital

Phil Austin

Founding Partner
Anterra Capital

Phil Austin

Founding Partner
Anterra Capital
 

Brett Morris

Principal, TechAccel LLC
Partner, Covenant Animal Health Partners LLC

Brett is a Principal for TechAccel LLC, a venture development and technology organization that invests across the agriculture, animal health, and food science industries. Brett leads venture investing and due diligence efforts for the firm and guides all corporate and asset-related transactions.

Brett Morris

Principal, TechAccel LLC
Partner, Covenant Animal Health Partners LLC

Brett Morris

Principal, TechAccel LLC
Partner, Covenant Animal Health Partners LLC

Brett is a Principal for TechAccel LLC, a venture development and technology organization that invests across the agriculture, animal health, and food science industries. Brett leads venture investing and due diligence efforts for the firm and guides all corporate and asset-related transactions.

He also serves as a Partner with Covenant Animal Health Partners LLC, a TechAccel subsidiary dedicated to the development and registration of “revenue-ready” animal health products. Covenant addresses critical market needs across production and companion animals and advances new assets into industry partner portfolios.

Prior to TechAccel, Brett worked in corporate development for a commodity trading and handling company focused in agriculture, feed, and energy. He helped source, evaluate, and execute mergers and acquisitions, equity investments, joint ventures, and organic growth initiatives. Further, he led efforts to assess the Agtech venture capital industry and evaluated startups in several areas including imagery, sensors, trading and logistics, and artificial intelligence. Prior to this, Brett worked for a small strategic advisory firm and a local bank.

Brett serves as a selection committee member for InvestMidwest and the Animal Health Investment Forum and volunteers as a mentor for the Techstars Farm to Fork Accelerator, the Sprint Corporate Accelerator Program and the Ag Innovation Showcase. He also serves as a guest lecturer for the Blue Valley CAPS program.

Brett graduated from the University of Kansas and is a CFA® charterholder. He is a member of the CFA Institute and the Kansas City CFA Society.

Email: [email protected]

LinkedIn https://www.linkedin.com/in/brett-morris-cfa-962a9023/

TechAccel website: www.TechAccel.net

Covenant Animal Health Partners website: www.CovenantAH.net



 

Daniel Promislow

Dog Aging Project Co-Director
U19 Principal Investigator

Daniel Promislow

Dog Aging Project Co-Director
U19 Principal Investigator

Daniel Promislow

Dog Aging Project Co-Director
U19 Principal Investigator
 

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.
 

Wesley Wierson

Founder & CEO
LEAH Labs

Wesley Wierson

Founder & CEO
LEAH Labs

Wesley Wierson

Founder & CEO
LEAH Labs
 

Dottie Brown

Senior Research Advisor, Translational Comparative Medical Research
Elanco

Dottie Brown

Senior Research Advisor, Translational Comparative Medical Research
Elanco

Dottie Brown

Senior Research Advisor, Translational Comparative Medical Research
Elanco
 

Bruce Taillon

Director External Innovation
Elanco

Bruce Taillon

Director External Innovation
Elanco

Bruce Taillon

Director External Innovation
Elanco
 

Wendy Vaala

Director of Scientific Marketing Affairs
Merck Animal Health

Wendy Vaala

Director of Scientific Marketing Affairs
Merck Animal Health

Wendy Vaala

Director of Scientific Marketing Affairs
Merck Animal Health
 

Fabian Kausche

Chairman
Stonehaven Incubate

Fabian Kausche

Chairman
Stonehaven Incubate

Fabian Kausche

Chairman
Stonehaven Incubate
 

Brian Axe

Principal
NovaQuest Capital Management

Brian Axe

Principal
NovaQuest Capital Management

Brian Axe

Principal
NovaQuest Capital Management
 

Matthew Salois

Chief Economist
AVMA

Matthew Salois

Chief Economist
AVMA

Matthew Salois

Chief Economist
AVMA
 

John Butler

CEO
The Beef Marketing Group

John Butler

CEO
The Beef Marketing Group

John Butler

CEO
The Beef Marketing Group
 

Kate E. Creevy

DVM, MS, DACVIM, Chief Veterinary Officer
The Dog Aging Project

Kate E. Creevy

DVM, MS, DACVIM, Chief Veterinary Officer
The Dog Aging Project

Kate E. Creevy

DVM, MS, DACVIM, Chief Veterinary Officer
The Dog Aging Project
 

Rimma Driscoll

Senior Vice President, Global Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure.

Rimma Driscoll

Senior Vice President, Global Business Development
Zoetis

Rimma Driscoll

Senior Vice President, Global Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

 

Scott Brown

VP External Innovation, Veterinary Medicine R&D
Zoetis

Scott Brown

VP External Innovation, Veterinary Medicine R&D
Zoetis

Scott Brown

VP External Innovation, Veterinary Medicine R&D
Zoetis
 

Janet Patterson-Kane

Chief Scientific Officer
Morris Animal Foundation

Janet Patterson-Kane

Chief Scientific Officer
Morris Animal Foundation

Janet Patterson-Kane

Chief Scientific Officer
Morris Animal Foundation

Partners

Headline Partner

Associate Partners

Event Partners

Media Partners

The Agenda

You can download our latest agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Download Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Wednesday, August 5, 2020 to Tuesday, September 1, 2020
Tier 1
$299
Super Early Bird Rate
Pre-revenue companies
Human Biotechs
Academics
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Wednesday, August 5, 2020 to Tuesday, September 1, 2020
Tier 2
$999
Super Early Bird Rate
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Pharmaceutical Companies
Animal Health Companies
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a $70 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

Global Advisory Board

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Jean-Luc Michel

Head of Global Strategic Marketing
Boehringer Ingelheim

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

George Gunn

Founder and CEO
Stonehaven Consulting AG

Linda Rhodes

Independent Animal Health Expert

Alan Mackay

Executive Partner and Founder
GHO Capital

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

Animal Health LatAm 2020

Animal Health Asia 2020

AH Europe 2021